 |
August 31, 2010 – Otoprotective effect of AM-111 also shown in cochlear ischemia
> |
 |
|
June 9, 2010 – Oliver Kubli joins Auris Medical’s Board of Directors
> |
|
|
December 30, 2009 – AM-111 prevents hearing loss from semicircular canal injury in otitis media
> |
|
|
March 13, 2009 – Auris Medical initiating phase IIb clinical trial with AM-101
> |
|
|
January 20, 2009 – Auris Medical initiating phase IIb clinical trial with AM-111
> |
|
|
September 25, 2008 – Auris Medical to present at RNID's Sensory Impairment Conference
> |
|
|
August 21, 2008 – Auris Medical reporting results of phase I/II clinical trial with AM-101
> |
|
|
February 15, 2008 – Auris Medical completes series B financing round
> |
|
|
January 30, 2008 – Auris Medical completing enrolment in phase I/II clinical trial with AM-101
> |
|
|
January 13, 2008 – New published data show otoprotective effect of AM-111 in case of inner ear inflammatory responses (acute labyrinthitis)
> |
|
|
February 22, 2007 – Auris Medical initiating phase I/II clinical trial with AM-101
> |
|
|
February 19, 2007 – New research data suggesting otoprotective effect of AM-111 also in acute labyrinthitis
> |
|
|
June 21, 2006 – Auris Medical reporting results of a phase I/II clinical trial with AM-111
> |
|
|
April 13, 2006 – Auris Medical’s AM-111 obtains FDA orphan drug designation for the treatment of acute sensorineural hearing loss
> |
|
|
February
2, 2006 – Auris presented as innovative
young small enterprise in leading French business magazine
> |
|
|
January
9, 2006 – Auris Medical initiating first clinical trial with AM-111
> |
|
|
October
14, 2005 – Auris Medical presenting new data on AM-111’s otoprotective efficacy
> |
|
|
June
23, 2005 – Auris Medical’s AM-111 obtains orphan drug designation for the treatment of acute sensorineural hearing loss in the European Union
> |
|
|
February
21, 2005 – New data confirms strong otoprotective effect of Auris Medical’s AM-111
> |
|
|
December
15, 2004 – Auris and Institute for Neuroscience of Montpellier receive award
> |
|
|
April
8, 2004 – Auris Medical and Institute for Neuroscience of Montpellier enter into collaboration agreement
> |
|
|
February
4, 2004 – Xigen and Auris Medical enter into collaboration and license agreement
> |
|
|
January
20, 2004 – Philipp Mekler joins Auris
Medical’s
Board of Directors
> |
|
